On June 21, Novo Nordisk announced the results of the Phase 3b STEPUP trial for non-diabetic obese patients at the American Diabetes Association (ADA) Scientific Conference in Chicago, according to the Novo Nordisk website. The data showed that during the 72-week treatment period, a higher dose of Wegovy (semaglutide 7.2 mg) could reduce the average weight of obese patients by 21% compared with placebo, with one-third of the subjects losing 25% or more. The safety and tolerability of the higher dose of Wegovy (7.2 mg) were consistent with the 2.4 mg dose.